Investors banking on improved revenue performance due to hig...
Investors banking on improved revenue performance due to high P/S ratio may face disappointment due to the negative growth outlook. This scenario poses a substantial risk to shareholders' investments and potential investors may end up paying a hefty premium.
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Price Is Out Of Tune With Revenues
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment